Of interest, TRIP6, is an upstream activator of the transcriptional co-activators YAP (or YAP1) and TAZ and are involved in the pathogenesis of NAFLD (Machado et al., 2015; Wang et al., 2016). Here, TRIP6 is linked to metabolic dysfunction-associated steatotic liver disease.